RT @GrupoTTD: 📍FRESCO-2: Fruquintinib en cáncer colorrectal metastásico refractario Fase III, 943 pacientes, 72%>3L previas (91% FTD/TPI p…
📍FRESCO-2: Fruquintinib en cáncer colorrectal metastásico refractario Fase III, 943 pacientes, 72%>3L previas (91% FTD/TPI previo y 48% REG previo) ⬆️SG: 7,4 vs 4,8 meses ⬆️SLP: 3,7 vs 1,8 meses ⬆️TCE: 56% vs 16% AES>grado 3: 63% vs 50% #TTDUpdat
A reminder of the FRESCO-2 study in @TheLancet investigating fruquintinib vs placebo as treatment of refractory metastatic #Colorectal cancer Fruquintinib treatment resulted in a significant and clinically meaningful benefit in OS compared with placebo h
@OncBrothers @FDAOncology @RenoHemonc @ErikaHamilton9 @YJanjigianMD @DrChoueiri @alshamsi2000 @drteplinsky @hoperugo @christine_lovly @rachnatshroff @esinghimd Did misread something? #fruquintinib had an OS improvement. https://t.co/GYM19MWoJC
The role of Fruquintinib, an orally administered kinase inhibitor that targets VEGFR 1, 2, and 3, in heavily pretreated metastatic colorectal cancer. https://t.co/iXDNTf7oFh https://t.co/ZkGnyfui4b
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
RT @ArndtVogel: 🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉…
🔥FDA approves fruquintinib in refractory metastatic colorectal cancer 👉Approval based on FRESCO-2 https://t.co/EW6rnYwDL7 👉mOS 7.4 vs 4.8 mo, HR 0.66 🧐Continues VEGF inhibition in CRC: small, but consistent benefit across all treatment lines @myESMO https
武田薬品 打診イン! フルキンチニブのFDA優先審査のdead lineが11/30です. FRESCO-2 studyではレゴラフェニブ不耐の大腸癌患者にも有意に奏功. 日本でも9/29に厚労省の製造販売承認申請済み. 大腸癌は罹患数1位で予後長めなので,薬剤の利用回数が多い. https://t.co/68Zc883Swx
フルチンニキ()がランセット!! https://t.co/SFThH11K6I
RT @TheLancet: There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal canc…
RT @TheLancet: There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal canc…
RT @TheLancet: There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal canc…
There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. A study evaluated the efficacy and safety of fruquintinib in patients with heavily pretreated metastatic colorectal cancer. 🧵 h
RT @realbowtiedoc: Congratulations @adasarimd and team on publication of FRESCO-2 supporting use of fruquintinib in refractory advanced/met…
Congratulations @adasarimd and team on publication of FRESCO-2 supporting use of fruquintinib in refractory advanced/metastatic #crcsm patients. https://t.co/MhFkfuvDBi #GIonc
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study https://t.co/Br3DUE7ULa #hvhebron #onco @TheLancet
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
$4502.JT | $TAK & $13.HK | $HCM.LN | $HCM Takeda & Hutchmed Announce Publication of Phase 3 FRESCO-2 Results in The Lancet https://t.co/5xvBCMA0n7 Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2):
👏
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study https://t.co/dl3Baodtld https://t.co/0YHBrmTElQ
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @Rob__Brierley: FRESCO-2: Fruquintinib for refractory metastatic #colorectalcancer 👉mOS 7·4 m (95% CI 6·7–8·2) w/ fruquintinib vs 4·8 m…
RT @CathyEngMD: For those wanting FREE ACCESS to the @TheLancet article re: #FRESCO2 #Fruquintinib @TakedaOncology @hutchmed @VUMCDiscoveri…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
For those wanting FREE ACCESS to the @TheLancet article re: #FRESCO2 #Fruquintinib @TakedaOncology @hutchmed @VUMCDiscoveries @VUMC_Cancer @VUMCHemOnc #Cancer #CancerResearch Please use this link until 8/4/2023: https://t.co/MEdFcpWbHo
RT @LancetGastroHep: New @TheLancet - Dasari et al - Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (…
RT @HH_Oncodr: And honored to co-author with @adasarimd, @CathyEngMD plus international team to bring another new drug to clinic for late-l…
And honored to co-author with @adasarimd, @CathyEngMD plus international team to bring another new drug to clinic for late-line #coloncancer. Thanks to entire @RutgersCancer @rwj team who worked on the trial. Bringing tomorrow’s treatment to you today @Ru
RT @pashtoonkasi: 👏🏾Congratulations Dr. @CathyEngMD! Options in the continuum of care continue to grow for patients with #ColorectalCancer…
RT @smitha42: Congratulations @CathyEngMD @adasarimd and colleagues! Will be so good to have another treatment option for our patients wit…
Ini definisi wong edan. Trial fase 3 utk kanker kolon metastatik, obat kok dilawan PLASEBO. Udah lawan plasebo, benefit nya kecil pula. Pharma rules us all?????
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @pashtoonkasi: 👏🏾Congratulations Dr. @CathyEngMD! Options in the continuum of care continue to grow for patients with #ColorectalCancer…
RT @pashtoonkasi: 👏🏾Congratulations Dr. @CathyEngMD! Options in the continuum of care continue to grow for patients with #ColorectalCancer…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
New Rx option for our CRC Pts🙏😊
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @pashtoonkasi: 👏🏾Congratulations Dr. @CathyEngMD! Options in the continuum of care continue to grow for patients with #ColorectalCancer…
RT @pashtoonkasi: 👏🏾Congratulations Dr. @CathyEngMD! Options in the continuum of care continue to grow for patients with #ColorectalCancer…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @pashtoonkasi: 👏🏾Congratulations Dr. @CathyEngMD! Options in the continuum of care continue to grow for patients with #ColorectalCancer…
👏🏾Congratulations Dr. @CathyEngMD! Options in the continuum of care continue to grow for patients with #ColorectalCancer. G12C⛔️ & FRUquintinib to be added soon. 💡In future, do you see FRUquintinib being explored with chemo, or more so with novel dr
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @drkpavithran: Fruquintinib (inhibitor of VEGFRs 1, 2, 3) improves overall survival (7·4 months Vs 4·8 months) in patients with refracto…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @smitha42: Congratulations @CathyEngMD @adasarimd and colleagues! Will be so good to have another treatment option for our patients wit…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
RT @smitha42: Congratulations @CathyEngMD @adasarimd and colleagues! Will be so good to have another treatment option for our patients wit…
RT @KerryCranberry: Exciting news from the CRC Research world. Improved overall survival is a great thing to hear. Exciting things are happ…
RT @ArndtVogel: 🔥Fruquintinib versus placebo in patients with refractory #CRC (FRESCO-2) @TheLancet https://t.co/zM4cXCnkPF 🔎🌍phs-3, 943 pt…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
Exciting news from the CRC Research world. Improved overall survival is a great thing to hear. Exciting things are happening in the research world. #CancerResearch #CancerSucks
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
RT @CathyEngMD: JUST OUT! Honored to serve as the senior author in @TheLancet re: Phase 3 FRESCO-2 #fruquintinib with improved OS and PFS.…
Fruquitinib data is now al-fresco in the Lancet. The wait continues for anticipated approval.